# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
DermTech (NASDAQ:DMTK) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.57) by...
Lake Street analyst Thomas Flaten downgrades DermTech (NASDAQ:DMTK) from Buy to Hold and announces $0.63 price target.
Stephens & Co. analyst Mason Carrico reiterates DermTech (NASDAQ:DMTK) with a Equal-Weight and maintains $1.5 price target.
BTIG analyst Sung Ji Nam downgrades DermTech (NASDAQ:DMTK) from Buy to Neutral.
The Company anticipates incurring a one-time restructuring charge of approximately $1.6 million in the second quarter of 2024 i...
Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business com...
BTIG analyst Mark Massaro maintains DermTech (NASDAQ:DMTK) with a Buy and lowers the price target from $4 to $2.